Skip to main content
. 2022 Feb 22;10:792676. doi: 10.3389/fcell.2022.792676

FIGURE 8.

FIGURE 8

Comparison of the expression of immune checkpoint genes and sensitivity to clinical treatment between high- and low-risk groups. (A) Expression of immune checkpoint genes among the two groups. (B) TIDE score of the two groups. (C) The signature can be used as a potential predictor of sorafenib sensitivity, as low-risk scores are associated with a lower IC50 for sorafenib.